Bio News
Dana-Farber Cancer Institute has discovered the first metabolically activated molecular glue through screening seven E3 ligases. The researchers identified the mechanism by which the molecular glue 'M12' is activated through glutathionylation in the oxidative-stress environment of cancer cells. Dana-Farber plans to use the technology to induce the degradation of at least three anticancer targets, including SMARCA2 and WEE1.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
